RECIST criteria are inadequate for measuring ... For this reason, The Prostate Cancer Clinical Trials Working Group has defined radiological progression as the development of two or more lesions ...

Jones Trading reiterated a Buy rating on ORIC Pharmaceuticals stock with a price target of $17.00, as shares traded at $11.23. The stock has shown remarkable momentum, gaining over 20% in the past ...

A new study by UC San Francisco found that prostate cancer cases are increasing in California, likely due to a change in ...

The RECIST-evaluable patients included patients ... have been implicated as important in castration-resistant prostate cancer. Synergistic anti-tumor activity has been reported with the sequential ...

Advanced prostate cancer cases are rising sharply in California, outpacing national trends, according to a new study from ...

The deal sees Endocyte acquire an exclusive worldwide licence for ABX’s phase 3-ready prostate cancer candidate 177Lu ... in 40% to 60% of patients, and a RECIST response rate in soft tissue ...